Diclofenac, a nonsteroidal anti-inflammatory drug, was associated with an up to 63% higher risk of cardiovascular events, and should be eliminated from essential-medicines lists, according to a meta-analysis published online in PLoS Medicine. Diclofenac was the most widely used NSAID in 15 countries, and its heart risk was comparable to that of rofecoxib, which was withdrawn from the market due to its cardiovascular toxocicty.
Analysis: Diclofenac's heart risks warrant caution
SmartBrief Job Listings for Health Care
|Junior to Mid-Level FDA Associate||
|Global Counsel - Advertising and Promotions||
|Associate Director, Compliance & Ethics, US Operations Ops II||
|Senior Associate, Health Economics - Heart Valve Therapy||
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||